Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437997 | 1.00 | KDM4E (0.50) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL23957563 | 0.86 | AR (0.42) | KDM4EPOLBRAB9AP2RX3P2RX2 | |
| SCHEMBL1980041 | 0.82 | KDM4E (0.48) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL13720853 | 0.81 | KDM4E (0.49) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL13721256 | 0.81 | KDM4E (0.57) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL15303508 | 0.80 | SLC22A12 (0.40) | KDM4EALDH1A1P2RX3ARSLC22A12 | |
| SCHEMBL9923978 | 0.80 | KDM4E (0.50) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL29438004 | 0.80 | KDM4E (0.50) | KDM4EPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL17571132 | 0.78 | XIAP (0.41) | POLBMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL1978329 | 0.78 | KDM4E (0.48) | KDM4EPOLBMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214090-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901152-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | KDM4E 200/4885POLB 3774/4885MEN1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.